With Lipid Nanoparticles (LNPs) at the forefront of medical innovation, Phosphorex understands that this groundbreaking technology is poised to revolutionize therapeutic nucleic acid delivery and shape the future of medicine.
With the commercial success of pioneering therapies like ONPATTRO®, COMIRNATY®, and SPIKEVAX®, the potential applications of LNPs have been validated and expanded. The market is now eager to witness the next generation of LNPs, unlocking even greater possibilities for delivering nucleic acids to extra-hepatic tissues and achieving cell-specific targeting.
For LNPs, our team at Phosphorex has years of experience in the following:
Formulation, process development, and analytics are interconnected. Advancing analytical method development in a stage appropriate manner is critical to ensure success of program from feasibility to clinical manufacture. Phosphorex’s analytical services for sustained release drug delivery systems include API characterization, physical characterization, and development stability studies.
Choose us for our unique access to proprietary ionizable lipids, diverse in-house mixing technologies, extensive downstream processing expertise, comprehensive analytical capabilities, and a flexible team of experts. Partner with us to unlock the full potential of LNPs and propel your therapeutic nucleic acid delivery to new heights. For more information on our LNP capabilities, email us email@example.com.